Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
Garassino MC
Cancer Res. 78(20):5729-5730. doi: 10.1158/0008-5472.CAN-18-2245
Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.
Sica A, Guarneri V, Gennari A
Cell Stress. 2019 Jul 1;3(9):284-294. doi: 10.15698/cst2019.09.197
Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages.
Di Martile M
J Immunother Cancer. 8(1)doi: 10.1136/jitc-2019-000489
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Locatelli SL
Clin Cancer Res. 2018 Oct 23;25(3):1098-1112. doi: 10.1158/1078-0432.CCR-18-1133
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
Consonni FM
Front Immunol. 2019 May 3;10:949. doi: 10.3389/fimmu.2019.00949
Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells.
Travelli C
Cancer Res. 2019 Feb 18;79(8):1938-1951. doi: 10.1158/0008-5472.CAN-18-1544
Membrane Cholesterol Regulates Macrophage Plasticity in Cancer.
Sica A, Bleve A, Garassino MC
Cell Metab. 29(6):1238-1240. doi: 10.1016/j.cmet.2019.05.011
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs.
Porta C
Cancer Res. 2020 Apr 7;80(13):2874-2888. doi: 10.1158/0008-5472.CAN-19-2843
Immunometabolic Status of COVID-19 Cancer Patients.
Sica A
Physiol Rev. 2020 Jul 28;100(4):1839-1850. doi: 10.1152/physrev.00018.2020
Implications of metabolism-driven myeloid dysfunctions in cancer therapy.
Strauss L
Cell Mol Immunol. 2020 Oct 19;18(4):829-841. doi: 10.1038/s41423-020-00556-w